AL
HRTX icon

Airain Ltd’s Heron Therapeutics HRTX Stock Holding History

Airain Ltd’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$442K Buy
+31,943
New +$463K 0.02% 567
2015
Q4 		– Sell
-14,536
Closed -$355K – 927
2015
Q3 		$355K Buy
+14,536
New +$484K 0.02% 560
2015
Q2 		– Sell
-26,278
Closed -$382K – 962
2015
Q1 		$382K Buy
+26,278
New +$296K 0.02% 573

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Airain Ltd's HRTX Position: Q2 2017 in Review

Airain Ltd opened a new position in Heron Therapeutics (HRTX) in Q2 2017: 31,943 shares worth $442K. The stake represents 0.02% of the portfolio and ranks #567 among its holdings. This is a return to the name: Airain Ltd previously reported a position in HRTX as recently as Q3 2015.

Airain Ltd first reported a position in HRTX in Q1 2015 and has held it in 3 quarters since. 104 funds tracked by Wall St. Rank hold HRTX as of Q2 2017.

  • Airain Ltd held 31,943 shares of Heron Therapeutics worth $442K as of Q2 2017.
  • Heron Therapeutics was a new Airain Ltd position in Q2 2017.
  • Heron Therapeutics made up 0.02% of Airain Ltd's portfolio in Q2 2017, its #567 holding.
  • Airain Ltd first reported a position in Heron Therapeutics in Q1 2015 and has held it in 3 quarters since.
  • 104 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.